Tempest Therapeutics, Inc. (NASDAQ: TPST) has entered a strategic partnership with Hebei Senlang Biotechnology Co., Ltd. to develop its proprietary TPST-4003 product candidate. The collaboration begins with an investigator-initiated trial (IIT) in China, evaluating TPST-4003 in approximately 10 patients with neurological autoimmune diseases, specifically myasthenia gravis (MG) and multiple sclerosis (MS). First patient enrollment and dosing are anticipated in the fourth quarter of 2026, with initial data readouts expected in the first half of 2027.

TPST-4003 is a next-generation in vivo CAR-T candidate that combines Tempest's proprietary CD7-targeted mRNA/LNP delivery approach with a dual-targeting CD19/BCMA CAR construct. This design aims to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indications. The platform differentiates itself through its mRNA/LNP delivery method, which targets CD7, a key marker in T-cell development, potentially reducing the complexity and cost associated with ex vivo cell manipulation.

Under the agreement, Senlang, a clinical-stage cell therapy company with extensive expertise in CD7-targeted CAR-T development, will coordinate and support trial execution in China. The study is designed to generate clinical evidence of safety, pharmacodynamic (PD) activity, and therapeutic potential, building on promising preclinical and clinical research findings. Additionally, the agreement grants Senlang an exclusive option to negotiate and enter into a definitive license agreement for TPST-4003 in China.

Tempest Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of advanced CAR-T product candidates. The advancement of TPST-4003 into clinical testing through this partnership marks a key milestone in the company's strategy to expand the application of CAR-T technology beyond oncology into immunology.

Tempest Therapeutics has filed a prospectus with the SEC for the offering of 2.427M common shares on behalf of selling shareholders. The filing outlines the details of the proposed sale, specifying that the shares are being offered by existing stakeholders rather than the company itself. This move allows selling shareholders to liquidate a portion of their holdings in the open market.

The prospectus provides regulatory documentation required for the transaction, ensuring compliance with securities laws. It does not indicate any new capital raise for Tempest Therapeutics, as the proceeds from the sale will go directly to the selling shareholders. The filing is a standard procedural step for such offerings.

Key Details of the Offering

The document serves as the primary source of information for potential investors regarding the specific terms and conditions of the share sale. It includes risk factors and other disclosures mandated by the SEC to protect investors.